Literature DB >> 16631329

Evaluation of brain-targeting for the nasal delivery of estradiol by the microdialysis method.

Xiaomei Wang1, Haibing He, Wei Leng, Xing Tang.   

Abstract

The uptake of estradiol into the cerebrospinal fluid (CSF) after intranasal and intravenous administration in rats was investigated to study whether direct nose-CSF transport of estradiol exits or not. Animals received 0.48 mg kg(-1) estradiol randomly methylated beta-cyclodextrin (RAMEB) inclusion complex intranasally and intravenously. Following nasal delivery, estradiol reached a C(max) value (mean+/-S.D.) in plasma (26.70+/-11.37 ng ml(-1)) and CSF (54.76+/-32.84 ng ml(-1)) after 20 min in each case, while after intravenous infusion, estradiol reached a C(max) value in plasma (170.08+/-64.67 ng ml(-1)) and CSF (26.48+/-11.34 ng ml(-1)) at 5 min and 60 min, respectively. The AUC(CSF)/AUC(plasma) ratio (1.60+/-0.67) after intranasal delivery differed significantly from the ratio (0.61+/-0.16) observed after intravenous infusion (P<0.05). All these results indicate that estradiol is transported into CSF via olfactory neurons, and, hence, there is a direct transport route from the nasal cavity into the CSF for estradiol.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631329     DOI: 10.1016/j.ijpharm.2006.02.055

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  10 in total

Review 1.  Getting into the brain: approaches to enhance brain drug delivery.

Authors:  Mayur M Patel; Bhoomika R Goyal; Shraddha V Bhadada; Jay S Bhatt; Avani F Amin
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

2.  2-hydroxypropyl-beta-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease.

Authors:  Sarah Ward; Patricia O'Donnell; Steven Fernandez; Charles H Vite
Journal:  Pediatr Res       Date:  2010-07       Impact factor: 3.756

3.  Nanotechnology for CNS delivery of bio-therapeutic agents.

Authors:  Lipa Shah; Sunita Yadav; Mansoor Amiji
Journal:  Drug Deliv Transl Res       Date:  2013-08-01       Impact factor: 4.617

Review 4.  First-line management of canine status epilepticus at home and in hospital-opportunities and limitations of the various administration routes of benzodiazepines.

Authors:  Marios Charalambous; Holger A Volk; Luc Van Ham; Sofie F M Bhatti
Journal:  BMC Vet Res       Date:  2021-03-04       Impact factor: 2.741

Review 5.  Restoration of olfactory dysfunctions by nanomaterials and stem cells-based therapies: Current status and future perspectives.

Authors:  Shin Hyuk Yoo; Hae-Won Kim; Jun Hee Lee
Journal:  J Tissue Eng       Date:  2022-03-23       Impact factor: 7.813

6.  Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study.

Authors:  Sanjar Alam; Zeenat I Khan; Gulam Mustafa; Manish Kumar; Fakhrul Islam; Aseem Bhatnagar; Farhan J Ahmad
Journal:  Int J Nanomedicine       Date:  2012-11-09

Review 7.  Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting.

Authors:  Fabio Sonvico; Adryana Clementino; Francesca Buttini; Gaia Colombo; Silvia Pescina; Silvia Stanisçuaski Guterres; Adriana Raffin Pohlmann; Sara Nicoli
Journal:  Pharmaceutics       Date:  2018-03-15       Impact factor: 6.321

8.  Tanshinol borneol ester on nanostructured lipid carriers has longer brain and systemic effector retention and better antioxidant activity in vivo.

Authors:  Xinyi Yuan; Fuhuan Fei; Huanmei Sun; Chaoni Xiao; Xinfeng Zhao; Yajun Zhang; Xiaohui Zheng
Journal:  Int J Nanomedicine       Date:  2018-04-12

Review 9.  Progress in drug delivery to the central nervous system by the prodrug approach.

Authors:  Barbara Pavan; Alessandro Dalpiaz; Nunzia Ciliberti; Carla Biondi; Stefano Manfredini; Silvia Vertuani
Journal:  Molecules       Date:  2008-05-01       Impact factor: 4.411

10.  Intranasal administration of oxytocin: behavioral and clinical effects, a review.

Authors:  Jan G Veening; Berend Olivier
Journal:  Neurosci Biobehav Rev       Date:  2013-05-04       Impact factor: 8.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.